| Name | Gresonitamab |
|---|
| Description | Gresonitamab (AMG 910) is a half-life extended (HLE) bispecific T-cell engager (BiTE) antibody targets CD3-positive T cells and CLDN18.2-expressing tumor cells. Gresonitamab can be used for the research of adenocarcinoma[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Gresonitamab 重定向肿瘤细胞裂解以杀死肿瘤细胞[1]。 |
| References |
| No Any Chemical & Physical Properties |